Barbara Ann Karmanos Cancer Institute

This phase II trial tests whether adding polatuzumab vedotin to standard chemotherapy improves outcomes for people with aggressive B-cell lymphomas, including double-hit and triple-hit lymphoma. The study enrolled 8 previously untreated patients. The goal is to see if the combina…

This study tests adding a drug called selinexor to the standard chemotherapy RCHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced or returning ly…